Cyclooxygenase-2 inhibitors have also been shown to be effective as a systemic approach for the prophylaxis of chemotherapy-associated HFS in patients with stage II and III colorectal cancer (14). The gene discussed is PTGS2; the disease is Hand-foot syndrome.